Bonkers Bargain: results reflect contract delays
This small medical imaging advanced analytics company delivering insights in neuroscience, had been growing fast over recent years and, following recent share price falls, looks cracking value. Our in-depth commentary here highlights its appeal in a sector which is predicted to grow significantly over the coming years. The order book offers plenty of visibility and this fascinating business is certainly worth a close look. Encouraging results from a drug being developed for Alzheimers disease is positive, although news of contract delays has pushed the shares lower.
IXICO (LON:IXI) is an Artificial Intelligence (‘AI’) data analytics company delivering intelligent insights in neuroscience. Its purpose is to advance medicine and human health in neuroscience by converting raw clinical trial data into clinically meaningful information.
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
- Podcasts
Previous article Next article
DON'T MISS OUT!
Get top investment ideas to help safeguard and grow your wealth.
Invaluable insight from the exciting world of smaller companies.
REGISTER FREE
More on IXICO PLC
Episode 19 of the Investor’s Champion Podcast
In this episode of the Investors Champion Podcast, hosts Lee and Chris discuss the latest stock…
Bonkers Bargain: results reflect contract delays
This small medical imaging advanced analytics company delivering insights in neuroscience, had been growing fast over…
